ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
May 30, 2023 11:00 JST
Source:
Avance Clinical
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
ADELAIDE, AUS & SAN DIEGO, May 30, 2023 - (ACN Newswire) - Avance Clinical, the leading award-winning Australian and North American CRO that offers ClinicReady and GlobalReady for early phase biotech companies to speed up the path to regulatory approval, says early phase oncology studies are increasingly more complex and demand more patients. Avance's ClinicReady and GlobalReady service platforms offer significant benefits to product development in oncology.
Avance Clinical's Chief Scientific Officer, Gabriel Kremmidiotis
According to Avance Clinical's Chief Scientific Officer Gabriel Kremmidiotis who is part of the Avance Clinical team attending ASCO:
"Recently, Phase I clinical trial designs in Oncology patients have become more elaborate and include elements of dose escalation, dose expansion and assessment of drug combinations. This, in addition to the increasing number of new emerging therapeutics, has increased the demand for fast progress through the early phases of development and a greater demand for access to patients."
"Utilizing Australia's regulatory environment and high-quality oncology experts, Avance Clinical is able to facilitate a fast project launch and seamless transition across different parts of modular oncology protocol designs. Studies start in Australia and, at appropriate stages, expand to the US as determined by patient accrual number requirements for each study."
"Retaining the majority of backend services (biostatistics, data management, pharmacokinetics and medical writing) in Australia ensures the highest degree of financial benefit for our clients through the Australian R&D tax incentive."
Avance Clinical CEO, Yvonne Lungershausen, Chief Scientific Officer Gabriel Kremmidiotis, and Head of Scientific and Regulatory Affairs Jorgen Mould are featured in a new Global Health video on Reuters news service about the importance of quality clinical trials as part of the drug development process.
The Global Health program brings together 100 leaders and executives from various sectors of the Private and Public Healthcare Industry.
Avance Clinical CEO, Yvonne Lungershausen and Executive VP North American Operations John Mann attended the Global Health Summit and Yvonne was a leading panelist.
Avance Clinical is at the cutting edge of clinical trial technology and has recently been ranked as the world leader in decentralised clinical trials (DCT) technology adoption by GlobalData and Clinical Trial Arena in the CRO sector.
The report found 46% of Avance Clinical's trials incorporated some elements of DCT technologies in 2022 including telemedicine, remote monitoring, and digital data collection. The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking. See the full report here.
https://www.clinicaltrialsarena.com/features/year-in-review-dct-2022/
Avance Clinical's unique GlobalReady offering enables biotechs that have completed early-phase trials in Australia to rapidly and seamlessly transition to the US in preparation for FDA approvals, all with the one CRO and dedicated teams across both regions, which reduces time and cost and delivers quality data.
There are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which demonstrates Australian data acceptability with the FDA and other major regulatory authorities. More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program.
This seamless GlobalReady journey is designed so biotechs can:
- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
Book a meeting with Avance Clinical at ASCO
https://www.avancecro.com/event/asco-2023-chicago-il/
Book a meeting with Avance Clinical at BIO Booth #2884
https://www.avancecro.com/event/4602/
Find out more:
Learn about the Australian Advantage here
https://www.avancecro.com/the-australian-advantage/
For more information about the benefits of running your next study with Avance Clinical
contact us:
enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their drug development phases that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase I and Beyond
Avance Clinical offers pre-clinical consultancy services with their experienced ClinicReady team right through to Phase I and beyond clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes that are available in Australia. With experience across more than 110 therapeutic indications, Avance Clinical can deliver world-class, high-quality, internationally accepted data suitable for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, Zelta, Veeva and Medrio are just some of Avance's technology partners.
www.avancecro.com
Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
NEC Solution Modernizes Network Infrastructure Construction Work
Feb 10, 2025 15:05 JST
Olympus Recognized on CDP's "A List", the Highest Rating in the Field of Climate Change
Feb 10, 2025 11:00 JST
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 07, 2025 17:40 JST
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
Feb 07, 2025 04:00 JST
MHI Thermal Systems to Launch New Model of the "Ene-Conductor" Heat Source Control System
Feb 06, 2025 16:51 JST
Hitachi establishes its fourth Corporate Venture Capital Fund to capture technology turning points and future growth opportunities
Feb 06, 2025 16:32 JST
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 05, 2025 17:46 JST
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 05, 2025 13:59 JST
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 05, 2025 13:56 JST
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 05, 2025 10:25 JST
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 04, 2025 18:41 JST
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2025 18:34 JST
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 04, 2025 17:38 JST
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 04, 2025 11:39 JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Feb 03, 2025 17:23 JST
MHI Group Presents "Best Innovation 2024" Awards for Products and Activities that Contribute to Solving Social Issues
Feb 03, 2025 14:31 JST
Fujitsu and Tokai National Higher Education and Research System leverage explainable AI to enhance space weather prediction in collaboration with JAXA
Feb 03, 2025 12:05 JST
Enjoy Anime Tokyo Station in the Metaverse! ANIME TOKYO STATION ON ROBLOX Opens at 3:00 p.m. on January 31, 2025!
Feb 01, 2025 08:00 JST
DENSO Announces Third Quarter Financial Results
Jan 31, 2025 18:09 JST
Rally Driver Hiroshi Masuoka Receives the Person of Sports Merit Award in Japan
Jan 31, 2025 15:12 JST
More Latest Release >>
Related Release
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
July 23 2024 16:00 JST
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 04 2024 22:00 JST
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
More Press release >>